Anti-HER2 ribozyme - Elan/Sirna
Alternative Names: Anti-HER2 ribozyme - Elan/Sirna; HerzymeLatest Information Update: 08 Jan 2008
Price :
$50 *
At a glance
- Originator Elan Pharmaceutical Technologies; Sirna Therapeutics
- Developer Sirna Therapeutics
- Class Antineoplastics; Ribozymes
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the adverse events and pharmacokinetics section
- 17 Apr 2003 Ribozyme Pharmaceuticals is now called Sirna Therapeutics